CA2148687A1 - Oligonucleotides antisens pour l'inhibition de l'expression de genes mutants et de genes de type sauvage dans le cas du collagene - Google Patents

Oligonucleotides antisens pour l'inhibition de l'expression de genes mutants et de genes de type sauvage dans le cas du collagene

Info

Publication number
CA2148687A1
CA2148687A1 CA002148687A CA2148687A CA2148687A1 CA 2148687 A1 CA2148687 A1 CA 2148687A1 CA 002148687 A CA002148687 A CA 002148687A CA 2148687 A CA2148687 A CA 2148687A CA 2148687 A1 CA2148687 A1 CA 2148687A1
Authority
CA
Canada
Prior art keywords
collagen
seq
oligonucleotide
sequence
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002148687A
Other languages
English (en)
Inventor
Darwin Prockop
Alain Colige
Renato Baserga
Paul Nugent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2148687A1 publication Critical patent/CA2148687A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002148687A 1992-11-09 1993-11-09 Oligonucleotides antisens pour l'inhibition de l'expression de genes mutants et de genes de type sauvage dans le cas du collagene Abandoned CA2148687A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97333292A 1992-11-09 1992-11-09
US07/973,332 1992-11-09

Publications (1)

Publication Number Publication Date
CA2148687A1 true CA2148687A1 (fr) 1994-05-26

Family

ID=25520770

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002148687A Abandoned CA2148687A1 (fr) 1992-11-09 1993-11-09 Oligonucleotides antisens pour l'inhibition de l'expression de genes mutants et de genes de type sauvage dans le cas du collagene

Country Status (4)

Country Link
EP (1) EP0674705A4 (fr)
JP (1) JPH08503366A (fr)
CA (1) CA2148687A1 (fr)
WO (1) WO1994011494A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808037A (en) * 1995-09-15 1998-09-15 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US5780611A (en) * 1995-09-15 1998-07-14 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US6156513A (en) * 1995-09-15 2000-12-05 Ramareddy V. Guntaka Oligmers which inhibit expression of collagen genes
GB9519299D0 (en) 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy
GB9604449D0 (en) * 1996-03-01 1996-05-01 Farrar Gwyneth J Genetic strategy ii
GB9606961D0 (en) * 1996-04-02 1996-06-05 Farrar Gwyneth J Genetic strategy III
US8551970B2 (en) 1996-04-02 2013-10-08 Optigen Patents Limited Genetic suppression and replacement
US5814500A (en) * 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
EP0973935A2 (fr) * 1997-03-20 2000-01-26 Variagenics, Inc. Genes cibles pour medicaments specifiques d'alleles
US6200754B1 (en) 1998-03-19 2001-03-13 Variagenics, Inc. Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
US6939712B1 (en) * 1998-12-29 2005-09-06 Impedagen, Llc Muting gene activity using a transgenic nucleic acid
GB9929487D0 (en) * 1999-12-15 2000-02-09 Zeneca Ltd Antisense oligonucleotides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006008C (fr) * 1988-12-20 2000-02-15 Donald J. Kessler Methode pour obtenir des oligonucleotides synthetiques qui se lient specifiquement a des sites cibles sur des molecules d'adn double brin, en formant un triplex colineaire; methode d'utilisation de ces oligonucleotides synthetiques
EP0666923A1 (fr) * 1991-09-05 1995-08-16 The University Of Connecticut Apport cible de polynucleotides ou d'oligonucleotides a des cellules

Also Published As

Publication number Publication date
JPH08503366A (ja) 1996-04-16
EP0674705A4 (fr) 1997-11-26
EP0674705A1 (fr) 1995-10-04
WO1994011494A1 (fr) 1994-05-26

Similar Documents

Publication Publication Date Title
JP3054745B2 (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
KR100316205B1 (ko) 평활근세포의증식을조절하기위한c-myc의안티센스억제
US20040002473A1 (en) Antisense oligonucleotides against VR1
Laptev et al. Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA
JPH10500309A (ja) リボザイムを用いて再狭窄および癌を治療するための方法および組成物
US10941404B2 (en) Treatment of angiopoietin like 7 (ANGPTL7) related diseases
CA2130264A1 (fr) Oligonucleotides capables de modifier la proliferation cellulaire
CA2135499A1 (fr) Methode et reagent pour l'inhibition de la cancerogenese
JPH09507502A (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
Wang et al. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2 (I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders.
US5866699A (en) Oligonucleotides with anti-MDR-1 gene activity
JPH1052264A (ja) Ｎ‐ｒａｓ発現阻害剤およびその方法
CA2148687A1 (fr) Oligonucleotides antisens pour l'inhibition de l'expression de genes mutants et de genes de type sauvage dans le cas du collagene
CA2250923A1 (fr) Traitements a base d'oligonucleotides et compositions contre les melanomes humains
US5683987A (en) Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
KR20000065690A (ko) 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법
WO1998032846A9 (fr) Traitement par acides nucleiques enzymatiques des maladies ou des etats lies aux niveaux de c-fos
WO1998032846A2 (fr) Traitement par acides nucleiques enzymatiques des maladies ou des etats lies aux niveaux de c-fos
Baertschi Antisense oligonucleotide strategies in physiology
US5861502A (en) Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
Matteucci et al. Sequence-defined oligonucleotides as potential therapeutics
JPH08506724A (ja) 白血病治療のための化合物および方法
EP0625194B1 (fr) Intensification de l'activite catalytique des ribozymes en utilisant un oligonucleotide de facilitation voisin
US5872007A (en) CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer
US6656731B1 (en) Nucleic acid catalysts with endonuclease activity

Legal Events

Date Code Title Description
FZDE Dead